Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature

Rasagiline is a monoamine oxidase type-B inhibitor used as monotherapy or in addition to levodopa in the treatment of Parkinson’s disease. Once daily administration of rasagiline makes it easy to use, and allows good compliance by patients and adherence to therapy. Several multicenter studies have n...

Descripción completa

Detalles Bibliográficos
Autores principales: Pistacchi, Michele, Martinello, Francesco, Gioulis, Manuela, Zambito Marsala, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381918/
https://www.ncbi.nlm.nih.gov/pubmed/26000219
http://dx.doi.org/10.1007/s40120-013-0014-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381918/
https://www.ncbi.nlm.nih.gov/pubmed/26000219
http://dx.doi.org/10.1007/s40120-013-0014-1

Ejemplares similares